Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Repurposing dasatinib for diffuse large B cell lymphoma.

Scuoppo C, Wang J, Persaud M, Mittan SK, Basso K, Pasqualucci L, Rabadan R, Inghirami G, Grandori C, Bosch F, Dalla-Favera R.

Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16981-16986. doi: 10.1073/pnas.1905239116. Epub 2019 Aug 5.

PMID:
31383760
2.

Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.

Ishibashi M, Toyoshima M, Zhang X, Hasegawa-Minato J, Shigeta S, Usui T, Kemp CJ, Grandori C, Kitatani K, Yaegashi N.

Sci Rep. 2018 Sep 4;8(1):13207. doi: 10.1038/s41598-018-31069-2.

3.

Personalized Cancer Models for Target Discovery and Precision Medicine.

Grandori C, Kemp CJ.

Trends Cancer. 2018 Sep;4(9):634-642. doi: 10.1016/j.trecan.2018.07.005. Epub 2018 Aug 8. Review.

PMID:
30149881
4.

CDK12: an emerging therapeutic target for cancer.

Lui GYL, Grandori C, Kemp CJ.

J Clin Pathol. 2018 Nov;71(11):957-962. doi: 10.1136/jclinpath-2018-205356. Epub 2018 Aug 13. Review.

PMID:
30104286
5.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

6.

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R, Moser RD, Park H, Gurley KE, Kao MC, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2018 Jun 15;24(12):2828-2843. doi: 10.1158/1078-0432.CCR-17-1339. Epub 2018 Mar 29.

7.

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; Cancer Genome Atlas Network.

Cell Syst. 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003.

8.

Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers.

Hasegawa-Minato J, Toyoshima M, Ishibashi M, Zhang X, Shigeta S, Grandori C, Kitatani K, Yaegashi N.

Oncotarget. 2017 Dec 15;9(3):3483-3496. doi: 10.18632/oncotarget.23322. eCollection 2018 Jan 9.

9.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

10.

Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases.

Wilson RA, Liu J, Xu L, Annis J, Helmig S, Moore G, Timmerman C, Grandori C, Zheng Y, Skapek SX.

Sci Rep. 2016 Feb 5;6:20376. doi: 10.1038/srep20376.

11.

Regulation of HBV-specific CD8(+) T cell-mediated inflammation is diversified in different clinical presentations of HBV infection.

Dinney CM, Zhao LD, Conrad CD, Duker JM, Karas RO, Hu Z, Hamilton MA, Gillis TR, Parker TM, Fan B, Advani AH, Poordad FB, Fauceglia PL, Kirsch KM, Munk PT, Ladanyi MP, Bochner BA, Bekelman JA, Grandori CM, Olson JC, Lechan RD, Abou GM, Goodarzi MA.

J Microbiol. 2015 Oct;53(10):718-24. doi: 10.1007/s12275-015-5314-y. Epub 2015 Oct 2.

PMID:
26428923
12.

Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.

Mishra R, Watanabe T, Kimura MT, Koshikawa N, Ikeda M, Uekusa S, Kawashima H, Wang X, Igarashi J, Choudhury D, Grandori C, Kemp CJ, Ohira M, Verma NK, Kobayashi Y, Takeuchi J, Koshinaga T, Nemoto N, Fukuda N, Soma M, Kusafuka T, Fujiwara K, Nagase H.

Cancer Sci. 2015 Apr;106(4):421-9. doi: 10.1111/cas.12610. Epub 2015 Mar 3.

13.

Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.

14.

Synthetic lethal screens as a means to understand and treat MYC-driven cancers.

Cermelli S, Jang IS, Bernard B, Grandori C.

Cold Spring Harb Perspect Med. 2014 Mar 1;4(3). pii: a014209. doi: 10.1101/cshperspect.a014209. Review. Erratum in: Cold Spring Harb Perspect Med. 2014 Apr;4(4). doi:10.1101/cshperspect.a023390.

15.

An unbiased in vivo screen reveals multiple transcription factors that control HPV E6-regulated hTERT in keratinocytes.

Xu M, Katzenellenbogen RA, Grandori C, Galloway DA.

Virology. 2013 Nov;446(1-2):17-24. doi: 10.1016/j.virol.2013.07.014. Epub 2013 Aug 8.

16.

A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets.

Grandori C.

Methods Mol Biol. 2013;1012:187-200. doi: 10.1007/978-1-62703-429-6_12.

PMID:
24006065
17.

Functional genomics to identify unforeseen cancer drug targets.

Kemp CJ, Grandori C.

Future Oncol. 2013 Apr;9(4):473-6. doi: 10.2217/fon.13.26. No abstract available.

PMID:
23560369
18.

PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.

Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, Porter C, Nelson PS.

Mol Cancer Res. 2013 Jun;11(6):568-78. doi: 10.1158/1541-7786.MCR-12-0710. Epub 2013 Mar 14.

19.

Functional genomics identifies therapeutic targets for MYC-driven cancer.

Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9545-50. doi: 10.1073/pnas.1121119109. Epub 2012 May 23.

20.

MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency.

Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, Morgan M, Kemp CJ, Grandori C.

Mol Cancer Res. 2012 Apr;10(4):535-45. doi: 10.1158/1541-7786.MCR-11-0508. Epub 2012 Feb 1.

21.

Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGFβ.

Wang ML, Walsh R, Robinson KL, Burchard J, Bartz SR, Cleary M, Galloway DA, Grandori C.

Cell Cycle. 2011 Aug 1;10(15):2540-8. Epub 2011 Aug 1.

22.

NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity.

Xu M, Katzenellenbogen RA, Grandori C, Galloway DA.

J Virol. 2010 Nov;84(21):11461-9. doi: 10.1128/JVI.00538-10. Epub 2010 Aug 25.

23.

MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.

Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C.

Cell Cycle. 2009 Sep 1;8(17):2756-68. Epub 2009 Sep 29.

PMID:
19652553
24.

c-Myc accelerates S-phase and requires WRN to avoid replication stress.

Robinson K, Asawachaicharn N, Galloway DA, Grandori C.

PLoS One. 2009 Jun 18;4(6):e5951. doi: 10.1371/journal.pone.0005951.

25.

NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes.

Xu M, Luo W, Elzi DJ, Grandori C, Galloway DA.

Mol Cell Biol. 2008 Aug;28(15):4819-28. doi: 10.1128/MCB.01969-07. Epub 2008 May 27.

26.

Epigenetic down-regulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc.

Benanti JA, Wang ML, Myers HE, Robinson KL, Grandori C, Galloway DA.

Mol Cancer Res. 2007 Nov;5(11):1181-9. Epub 2007 Nov 2.

27.

Non-transcriptional control of DNA replication by c-Myc.

Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R.

Nature. 2007 Jul 26;448(7152):445-51. Epub 2007 Jun 27.

PMID:
17597761
28.

Regulation of telomerase by human papillomaviruses.

Galloway DA, Gewin LC, Myers H, Luo W, Grandori C, Katzenellenbogen RA, McDougall JK.

Cold Spring Harb Symp Quant Biol. 2005;70:209-15.

PMID:
16869756
29.

Activation by c-Myc of transcription by RNA polymerases I, II and III.

Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, Goodfellow SJ, Athineos D, Zhang J, Ramsbottom BA, Innes F, Kantidakis T, Kerr ER, Brodie J, Grandori C, White RJ.

Biochem Soc Symp. 2006;(73):141-54. Review.

PMID:
16626295
30.

c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I.

Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ.

Nat Cell Biol. 2005 Mar;7(3):311-8. Erratum in: Nat Cell Biol. 2005 May;7(5):531.

PMID:
15723054
31.

Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest.

Von Kobbe C, May A, Grandori C, Bohr VA.

FASEB J. 2004 Dec;18(15):1970-2. Epub 2004 Sep 30.

PMID:
15459124
32.

Functional link between Myc and the Werner gene in tumorigenesis.

Grandori C, Robinson KL, Galloway DA, Swisshelm K.

Cell Cycle. 2004 Jan;3(1):22-5. Review.

PMID:
14657658
33.

Werner syndrome protein limits MYC-induced cellular senescence.

Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, Frank S, Amati B, Dalla-Favera R, Monnat RJ Jr.

Genes Dev. 2003 Jul 1;17(13):1569-74.

34.

Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc.

Felton-Edkins ZA, Kenneth NS, Brown TR, Daly NL, Gomez-Roman N, Grandori C, Eisenman RN, White RJ.

Cell Cycle. 2003 May-Jun;2(3):181-4. Review.

PMID:
12734418
35.

Direct activation of RNA polymerase III transcription by c-Myc.

Gomez-Roman N, Grandori C, Eisenman RN, White RJ.

Nature. 2003 Jan 16;421(6920):290-4.

PMID:
12529648
36.

Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1.

Iritani BM, Delrow J, Grandori C, Gomez I, Klacking M, Carlos LS, Eisenman RN.

EMBO J. 2002 Sep 16;21(18):4820-30.

37.
38.

The Myc/Max/Mad network and the transcriptional control of cell behavior.

Grandori C, Cowley SM, James LP, Eisenman RN.

Annu Rev Cell Dev Biol. 2000;16:653-99. Review.

PMID:
11031250
39.

Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5.

40.

The Mad protein family links transcriptional repression to cell differentiation.

McArthur GA, Laherty CD, Quéva C, Hurlin PJ, Loo L, James L, Grandori C, Gallant P, Shiio Y, Hokanson WC, Bush AC, Cheng PF, Lawrence QA, Pulverer B, Koskinen PJ, Foley KP, Ayer DE, Eisenman RN.

Cold Spring Harb Symp Quant Biol. 1998;63:423-33. Review. No abstract available.

PMID:
10384307
41.

Direct activation of TERT transcription by c-MYC.

Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R.

Nat Genet. 1999 Feb;21(2):220-4.

PMID:
9988278
42.

Myc target genes.

Grandori C, Eisenman RN.

Trends Biochem Sci. 1997 May;22(5):177-81. Review.

PMID:
9175477
43.

Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.

Grandori C, Mac J, Siëbelt F, Ayer DE, Eisenman RN.

EMBO J. 1996 Aug 15;15(16):4344-57.

44.

The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.

Hurlin PJ, Ayer DE, Grandori C, Eisenman RN.

Cold Spring Harb Symp Quant Biol. 1994;59:109-16. Review.

PMID:
7587059
45.

c-yes protein kinase is associated with a 38 kD protein in cerebellum.

Grandori C, Sudol M, Hanafusa H.

Oncogene. 1991 Jun;6(6):1063-6.

PMID:
2067844
46.

Regulation of kinase activity.

Grandori C.

Nature. 1989 Apr 6;338(6215):467. No abstract available.

PMID:
2927508
47.
48.
49.

Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein.

Kato JY, Takeya T, Grandori C, Iba H, Levy JB, Hanafusa H.

Mol Cell Biol. 1986 Dec;6(12):4155-60.

50.

Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV).

De Vecchis L, Graziani G, Macchi B, Grandori C, Pastore S, Popovic M, Gallo RC, Bonmassar E.

Leuk Res. 1985;9(3):349-55.

PMID:
2987620

Supplemental Content

Loading ...
Support Center